SENSEX NIFTY
Sanofi India > Company History > Pharmaceuticals > Company History of Sanofi India - BSE: 500674, NSE: SANOFI
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Sanofi India
Sanofi India
BSE: 500674|NSE: SANOFI|ISIN: INE058A01010|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jul 28, 17:00
2978.95
13.95 (0.47%)
VOLUME 104
LIVE
NSE
Aug 01, 17:00
2904.00
-49.75 (-1.68%)
VOLUME 1,977
Company History - Sanofi India
1956
 
 - The Company was incorporated as Hoechst Fedco Pharma Pvt. Ltd. on
 31st March.  The word `Private' was deleted on 19th April, 1961 as
 the
 Company was deemed to be Public Limited Company under Section 41-A
 of
 the Act.
 
 - The Company manufacture bulk drugs, drug intermediates, veterinary
 formulations and pesticides.  They established with financial and
 technical collaboration of Farbwerke Hoechst AG (now Hoechst AG),
 West
 Germany, which is one of the largest chemical and pharmaceutical
 manufacturing groups in the world.
 
 - Under the Licence and Technical Collaboration Agreement dated 11th
 July, made between Hoechst AG and the Company, the Company was inter
 alia granted the right to use the word `HOECHST' in its corporate
 name
 and the use of the trade marks owned by Hoechst AG in India in
 respect
 of various pharmaceutical preparations which would be manufactured
 and
 marketed by the Company in India on the terms and conditions
 mentioned
 in the said Agreement.
 
 - 10,000 Pref. and 10,000 No. of Equity shares of Rs 100 each issued
 to
 promoters.  5000 Pref. and 9,867 No. of Equity shares as Rights in
 proportion to holdings.
 
 1957
 
 - The Company set up a manufacturing unit at Mulund, for production
 of
 basic drugs.  In also manufactures intermediates including some of
 the
 latest discoveries in the Hoechst Group involving high technology
 and
 application of sophisticated modern manufacturing techniques.  It
 also
 supplies basic drugs to other pharmaceutical companies in India as
 well
 as to Europe.
 
 1961
 
 - 28,133 No. of Equity shares issued as Rights.
 
 1967
 
 - 37,800 bonus equity shares issued, propn., 3:5.  In June and
 August,
 17,000 No. of Equity shares issued as Rights.
 
 1969
 
 - 57,222 Bonus equity shares issued in the proportion 49:100.
 
 1974
 
 - 1,64,990 Bonus equity shares issued in the proportion 94:100,
 
 1979
 
 - 1,70,256 Bonus equity shares issued in the proportion 1:2.
 
 1982
 
 - The Company set up a manufacturing unit at the Kandla Free Trade
 Zone
 to cater to the increasing export market for its products.
 
 - 2,55,384 Bonus equity shares issued in the proportion 1:2.
 
 1984
 
 - The main objects of the public issue was to achieve the voluntary
 dilution of Hoechst AG's holding in the Company from 50% to 40% and
 also to provide the requirements of long term resources for capital
 expenditure to be incurred on account of normal replacement and
 renovation of capital assets, continuous modernisation and
 upgradation
 programmes to achieve efficiency and use of the lates techniques and
 methods of manufacture to impart high quality and sophistication to
 the
 product range.
 
 - 1,19,538 No. of equity shares issued (Prem. of Rs 100 per share)
 in
 July, of which 3,800 shares to business associates and 9,600 shares
 to
 employees including working directors) were reserved for
 preferential
 allotment.  The balance 1,78,138 shares offered for public
 subscription.
 
 1986
 
 - The Land and building water works, plant and machinery of the
 Company
 were revalued as on 31st December.
 
 - A new company under the name Hoechst Nepal Pvt. Ltd., was
 incorporated as a subsidiary of the Company in February in Nepal.
 
 1987
 
 - A new extension of the Haemaccel plant at Mulund and a
 multi-purpose
 fine chemicals plant for bulk drugs at Ankleshwar went into
 commercial
 production.
 
 - During the year, an industrial licence was obtained for the
 manufacture of Petoxifylline (TRENTAL), 2 tonnes of
 Ciclopiroxolamine
 (BATRAFEN), an antifungal drug and 5.30 lakhs TPA of diagnostic
 reagents at Ankleshwar.
 
 1988
 
 - Industrial licence was, received for the manufacture of 2 lakh
 doses
 of purified chick embroy cell culture vaccine (Human rabies vaccine)
 known as RABIPUR.
 
 - The Company obtained Central Government approval under the
 M.R.T.P.
 Act, 1969 to the establishment of a new undertaking for producing,
 processing and selling hybrid and high - yielding varieties of
 seeds.
 
 - The Company issued 2,30,000 - 14% secured redeemable
 non-convertible
 debentures of Rs 100 each on private placement basis.  These are
 redeemable at a premium of Rs 5 per debenture on 1st February, 1996.
 
 1989
 
 - The Company re-entered the antifugual market with the introduction
 of
 BATRAFEN which was an original research product of the Company's
 collaborators Hoechst AG, West Germany.
 
 - The Company introduced a new insecticide HOSTATHION.  FLAVOMYCIN,
 a modern performance promoter for poultry was launched during the
 year.
 
 - The Pharma formulation plant was commissioned at Ankleshwar in
 October, liquid injectible automatic filling line was commissioned
 in
 Mulund in September.
 
 1990
 
 - New pharma products introduced were TARIVID (a modern oral
 antibacterial), AVIL retard (sustained release formulation for
 treatment of allergies) and TABLON (a formulation containing
 Ibuprofen
 for the treatment of pain).
 
 - In co-operation with Boots Pharmaceuticals Ltd., a new
 anti-arthritic
 drug `FLUROFEN' was introduced.
 
 - A letter of intent were received for BARALGAN Ketone and
 fomulations,
 Glybenclamide and formulations, Hostathion technical and
 formulations,
 Fenbendazole substance and formulations and Ethion technical and
 formulations at the Company's works in Ankleshwar.  Industrial
 license
 was received for manufacture of LASIX retard besides receiving
 endorsement for manufacture of 13 tonnes of AVIL maleate.
 
 1991
 
 - A new herbicide Klass (Diuron) was introduced during the year.
 `Butox' and `Tolzan' were the new products introduced for external
 and
 internal parasites.
 
 - Industrial licences were received for manufacture of Tonophosphan,
 Berenil and Fenbendazole and their formulations at Ankleshwar. 
 Letters
 of intent were received for manufacture of Novalgin tablets and
 Roxatidine and their formulations at Ankleshwar and Lasiride and
 Betrafen and their formulations at Mulund.
 
 - The Company revalued its free-hold land, buildings etc and the net
 surplus of Rs 470,733,868 arising out of its was transferred partly
 to
 capital reserve (Rs 149,489,737) and to Revaluation reserve (Rs
 321,244,131).
 
 1992
 
 - A modern anti hypertensive `Rene Dil' and latest anti-ulcer drug.
 `Rotane' were introduced during the year.
 
 - Industrial licences were received for manufacture of Baralgan,
 Glybenclamide, and their formulations, Roxatidine, Lasiride and
 formulations and Novalgin tablets at Ankleshwar and Batrafen
 formulations at Mulund.
 
 - Letters of intent were received for manufacture of Ranipril and
 formulations, Tabalon tablets and Tarivid tablets at Ankleshwar and
 cosavil syrup and Streptase formulations at Mulund.
 
 - An additional super centrifuge and auxilliary equipments for the
 PCEC
 plant in Ankleshwar were installed and commissioned.
 
 1993
 
 - 19,38,411 No. of Equity shares of Rs 10 each issued at a premium
 of
 Rs 60 per share to Hoechst AG to raise its capital from 40% to 51%.
 
 1994
 
 - A product cardare, an ACE inhibitor was introduced.  An oral
 typhoid
 vaccine called typhonal was also introduced.  Candur-R, and
 antirabies
 vaccine was launched during the year.
 
 - With effect from 1st April, the Scheme of Arrangement was
 sanctioned
 for transfer of the company's agrochemicals division to Hoechst
 Schering Agrofoo Ltd.  In terms of the scheme every shareholder of
 the
 Company holding 50 shares, were allotted 10 shares of Rs 10 each of
 Hoechst Schering Agrofoo Ltd. without any payment.
 
 - Roussel India, Ltd. in which the Company held 4,18,560 No. of
 equity
 shares out of 6,27,840 No. of equity shares of Rs 100 each issued is
 a
 subsidiary of the Company.
 
 - 115,15,311 shares issued at a bonus shares in proportion 1:1.
 
 1995
 
 - The new products such as ACE inhibitor, Cardace etc. was
 attributed.
 The Company launched INSUMAN (human insulin) apart from Floxidin a
 new
 broad spectrum antibiotic.  Due to the technical difficulties, the
 Company had to close both foot and mouth disease vaccine and Candur
 DHL
 plants.
 
 - Roussel India Ltd., the Company's subsidiary was amalgamated with
 the
 Company.  Accordingly the name of the Company was changed to Hoechst
 Marion Roussel Ltd., effective 1st January, 1996.
 
 1996
 
 - `Insuman' an anti-diabetic drug was launched.  The production of
 `Baralgan' was suspended as per the Govt. order.
 
 - The capacity of Rabipur plant at Ankleshwar was expanded from 1.8
 million doses to 3.5 million doses per annum to meet the increased
 demand for the product.
 
 - The Company proposed to set up a joint venture company with Chiron
 Corporation, USA for manufacture of vaccines of Chiron group.  The
 company proposed to take up 49% of the share capital of the said
 company.
 
 1997
 
 - The Company proposed to introduce four new products viz. Frisium
 (anti-epileptic).  Amaryl (oran anti-diabetic) cefrom (4th
 generation
 cephalosporin) and Targocil (Glycopeptide)
 
 - The German drug multinational Hoechst Roussel is buying out the
 equity stakes of Colour Chem and two individual entrepreneurs in its
 Indian joint venture, Hoechst Roussel Vet Private Limited, to
 convert
 it into a fully-owned subsidiary.
 
 - Currently, Hoechst Roussel Vet GmbH, along with its subsidiary
 Hoechst Schering Agrevo Ltd, holds 51 per cent equity in the joint
 venture.
 
 - Hoechst-Huabei Pharmaceuticals Co. Ltd, is a 50:50 greenfield
 joint
 venture between Hoechst Marion Roussel and North china
 Pharmaceutical
 Group Corporation (NCPC).
 
 - Hoechst Marion Roussel recently forged a manufacturing joint
 venture
 for vaccines with the Chiron group in India.
 
 1998
 
 - Hoechst Marion Roussel (HMR), a 51 per cent subsidiary of Hoechst
 Marion Roussel, Germany, has a significant presence in
 pharmaceutical
 and agrochemicals industries.
 
 - The new joint venture company will manufacture the anti rabies
 vaccine Rabipur and other vaccines of the Chiron Group.
 
 - HMRL had purchased the 33.33 per cent shareholding of Roussel
 Laboratories UK in Roussel India, to make the latter a 100 per cent
 subsidiary of HMRL.
 
 - The company is all set to transfer its animal healthcare business
 to
 a joint venture company, in which HMR will have a 49 per cent stake
 and
 Chiron Corporation of the US 51 per cent.
 
 - Hoechst proposes to enter into a joint venture with Chiron
 Corporation of USA for the manufacture of vaccines.
 
 1999
 
 - Hoechst Marion Roussel has launched a voluntary retirement scheme
 (VRS) at its Mulund factory in Mumbai.
 
 2000
 
 - The Company plans to introduce variants of brands like Allegra and
 Tavanic in the domestic market.
 
 - The Company has re-designated Ramesh Subrahmanian as deputy
 managing
 director of the company with effect from 1st July.
 
 - The Company and Rhone-Poulenc Rorer (India) Ltd. two separate
 Indian
 subsidiaries of the French Pharmaceuticals and Chemicals major,
 Aventis
 SA, are implementing employee stock option schemes as part of the
 parent company's worldwide strategy.
 
 - Hoechst Marion Roussel Ltd. will acquire 29,55,608 No. of Equity
 shares of Rhone-Poulenc Rorer at Rs 15 per share.
 
 - Hoechst Marion Roussel will now be known as Aventis Pharma even as
 it
 aims to maintain a leading position within the Indian pharma sector.
 
 2002
 
 -Aventis Pharma Ltd has informed that the Board of Directors of the
 company has, at its meeting held on October 30, 2002 appointed Mr W
 Wagner as a Director of the company in the casual vacancy caused by
 resignation of Mr J Silvestre.
 
 -Bombay High Court sanctions amalgamation of Rhone-Poulenc Rorer
 with Aventis  Pharma Ltd.
 
 -Aventis Pharma increased its sales to Rs.261cr by 16% as against 
 the corresponding 
 period of the previous year.
 
 2003
 
 -Aventis Pharma Ltd has filed a lawsuit against  alleging patent
 infringement  on Six Orange 
 Book patent .
 
 -CRISIL withdrew its AAA rating for the Rs.30cr non-convertible
 Debenture issue
 of Aventis Pharma Ltd.
 
 -Mr.M.G. Rao  and Dr.S Bhattacharya have been appointed as Alternate
 Directors to
 Dr.Carlo de Notaristefani and Mr.W.W.Wagner.
 
 -Aventis Pharma has appointed Mr.Ramesh Subramanian, MD as the
 Vice-president
 of the Respiratory Sales for North-East and Mid-Atlantic US.
 
 2004
 
 -Aventis Pharma Ltd has informed that the Company had entered into a
 Joint Venture (JV) Agreement in April 1998 with Chiron Corporation,
 USA (Chiron) for the manufacture of the anti-rabies vaccine, Rabipur
 and for the grant of distribution rights in India to the Company for
 certain Chiron vaccines. 
 
 
 2007
 
 -Aventis Pharma Limited has appointed Mr. Eric Le-Bris as an
 Additional Director.
 
 -Aventis Pharma Limited has appointed Mr. S.C. Ghoge as Alternate
 Director to Mr. Eric Le-Bris. Mr. Ghoge being an employee of the
 Company, has been appointed a Wholetime Director.
 
 2008
 
 -Mumbai: Aventis Pharma has launched insulin drug Lantus in a
 prefilled disposable pen called Solostar.
 
 2010
 
 - Aventis Pharma Ltd has informed about the following changes which
 have taken place in the Board of Directors of the Company:
 
 
 1. Mr. M. Dargentolle, Chief Financial Officer of the Company who was
 Alternate Director to Mr. O. Charmeil has been appointed a Director of
 the Company with effect from July 19, 2010.
 
 2. Mr. J. M. Georges, Director, Industrial Pharma Intercontinental of
 the sanofi-aventis Group and Mr. F. X. Duhalde, Director - Finance &
 Administration of the sanofi-aventis Group, have been appointed as
 Additional Directors of the Company with effect from July 29, 2010.
 
 2011
 
 - Aventis Pharma Limited Acquisition of Nutraceutical Business of
 Universal Medicare Private Limited
 
 - Sanofi India, in association with HealthCare Global Enterprises
 Ltd, has launched an exclusive Fun Center for pediatric patients in
 Bangalore, Karnataka
 
 2012
 
 - Sanofi India launches re-usable insulin pen AllStar for Indian
 patients
 
 - Sanofi appoints Susheel Umesh as Head of Commercial Operations for
 its Pharmaceutical Operations in India
 
 -Company has changed its name from Aventis Pharma Ltd. to Sanofi
 India Ltd.                                                          
                                                        
 
Source : Dion Global Solutions Limited
Quick Links for Sanofi India
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.